14.2 Infectious Diseases: HIV/AIDS, Viral Hepatitis & STI Transmission

14.2 Infectious Diseases: HIV/AIDS, Viral Hepatitis & STI Transmission

[!IMPORTANT] De-Siloing Infectious Disease Care in Behavioral Health Settings: The syndemic convergence of substance use disorders, bloodborne pathogens, and sexually transmitted infections (STIs) represents one of the most formidable public health challenges in modern addiction medicine. Substance use accelerates infectious disease transmission through two interwoven vectors: biological direct inoculation (sharing unsterile syringes, cookers, and filtration cottons) and behavioral disinhibition (intoxication-driven condomless sex or exchanging sex for drugs or shelter). Addiction treatment programs must function as comprehensive healthcare gateways, offering universal screening, rapid biomedical prophylaxis, harm reduction education, and direct linkage to curative treatment.

Master's-level addiction counselors operate on the frontline of public health surveillance. When clinicians normalize screening, dispel pervasive medical myths, explain revolutionary biomedical concepts such as U=U and curative Hepatitis C therapies, and coordinate care across multidisciplinary teams, they save lives and eradicate community transmission reservoirs.

---

Human Immunodeficiency Virus (HIV/AIDS) in Addiction Care

HIV is a human retrovirus that selectively targets and destroys CD4+ T-helper lymphocytes, crippling cell-mediated immunity. Without antiretroviral treatment, the infection progresses from acute retroviral syndrome through a period of clinical latency to Acquired Immunodeficiency Syndrome (AIDS), clinically defined as a CD4 count falling below 200 cells/mm³ or the manifestation of opportunistic infections (such as Pneumocystis jirovecii pneumonia, toxoplasmosis, cryptococcal meningitis, or Kaposi sarcoma).

+-----------------------------------------------------------------------------------+
|                 BIOMEDICAL HIV PREVENTION & TREATMENT CASCADE                     |
+-----------------------------------------------------------------------------------+
| 1. UNIVERSAL OPT-OUT SCREENING:                                                   |
|    * 4th-generation antigen/antibody combo test (detects p24 antigen & antibodies)|
|    * Reduces diagnostic window to 2-4 weeks; opt-out framework normalizes testing |
+-----------------------------------------------------------------------------------+
| 2. PRE-EXPOSURE PROPHYLAXIS (PrEP):                                               |
|    * Daily oral TDF/FTC (Truvada) or TAF/FTC (Descovy); or bi-monthly IM          |
|      Cabotegravir (Apretude) -> Reduces sexual risk ~99%, injection risk >= 74%.  |
+-----------------------------------------------------------------------------------+
| 3. POST-EXPOSURE PROPHYLAXIS (PEP):                                               |
|    * Emergency 28-day 3-drug antiretroviral regimen initiated <= 72 HOURS.        |
+-----------------------------------------------------------------------------------+
| 4. ANTIRETROVIRAL THERAPY (ART) & U=U:                                            |
|    * Lifelong combination ART suppresses plasma viral load < 200 copies/mL.       |
|    * U=U: Undetectable = Untransmittable (Zero sexual transmission risk).         |
+-----------------------------------------------------------------------------------+

Universal "Opt-Out" Screening

The CDC and SAMHSA recommend universal opt-out HIV screening for all clients entering substance use disorder treatment. Under an opt-out protocol, testing is presented as an integral, routine component of standard clinical admission, performed automatically unless the client explicitly objects in writing. Opt-out testing dismantles stigma, eliminates clinical profiling, and dramatically increases diagnostic capture. Modern 4th-generation combination immunoassays detect both HIV-1/HIV-2 antibodies and the viral p24 antigen, identifying infection within 2 to 4 weeks of exposure and significantly narrowing the diagnostic "window period."

Biomedical Prophylaxis: PrEP and PEP

1. Pre-Exposure Prophylaxis (PrEP): Biomedical prevention for individuals at ongoing elevated risk of HIV acquisition:
   • Regimens: Daily oral emtricitabine/tenofovir disoproxil fumarate (TDF/FTC, Truvada) or emtricitabine/tenofovir alafenamide (TAF/FTC, Descovy), or every-two-month long-acting intramuscular cabotegravir injections (Apretude).
   • Efficacy: Daily oral PrEP reduces the risk of acquiring HIV from sexual contact by approximately 99% and reduces the risk from injection drug exposure by at least 74% to 84% when taken consistently.
   • Counselor Role: Identify candidates during intake (active injection use, sharing equipment, condomless sex), dispel myths, and facilitate warm handoffs to prescribing clinicians.
2. Post-Exposure Prophylaxis (PEP): Emergency medical protocol following an isolated, high-risk exposure (e.g., needle-stick injury, shared syringe with a person of unknown/positive HIV status, or condomless sexual assault):
   • The 72-Hour Rule: PEP consists of a 28-day course of three antiretroviral medications and must be initiated as soon as possible and strictly within 72 hours of exposure. Efficacy drops precipitously with each hour of delay. Counselors must route clients immediately to emergency departments or urgent care clinics.

The Science of Undetectable = Untransmittable (U=U)

Landmark prospective, multinational clinical trials—most notably the PARTNER 1, PARTNER 2, and Opposites Attract studies—monitored tens of thousands of condomless sexual acts between serodiscordant couples. These trials yielded an unequivocal result: Zero documented cases of linked sexual HIV transmission occurred when the HIV-positive partner maintained an undetectable viral load.

• Clinical Standard: When an individual achieves and maintains an undetectable viral load (defined as <200 copies/mL of blood) for at least six months on combination Antiretroviral Therapy (ART), there is effectively zero risk of sexually transmitting HIV to an HIV-negative partner.
• Counseling Integration: U=U is a transformative clinical tool. Addiction counselors utilize U=U to dissolve profound internal shame, alleviate transmission anxiety, support relationship intimacy, and motivate strict, daily adherence to ART.

---

Viral Hepatitis: Hepatitis A, B & C

Viral hepatitis causes acute and chronic necroinflammatory destruction of hepatocytes. In substance-using populations, Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV) represent catastrophic public health threats:

+-----------------------------------------------------------------------------------+
|                    VIRAL HEPATITIS: CLINICAL COMPARISON MATRIX                    |
+-----------------------------------------------------------------------------------+
| Dimension        | Hepatitis B Virus (HBV)        | Hepatitis C Virus (HCV)       |
+------------------+--------------------------------+-------------------------------+
| Viral Family     | Hepadnaviridae (dsDNA virus)   | Flaviviridae (ssRNA virus)    |
+------------------+--------------------------------+-------------------------------+
| Primary Route    | Bloodborne, sexual fluids,     | Primarily bloodborne          |
| of Transmission  | perinatal/vertical.            | (injection/snorting equipment)|
+------------------+--------------------------------+-------------------------------+
| Environmental    | **Extremely stable**: persists | Less stable: persists in      |
| Stability        | on dry surfaces for > 7 days.  | syringes up to several weeks. |
+------------------+--------------------------------+-------------------------------+
| Chronicity Rate  | ~5% in immunocompetent adults; | **75% to 85%** of acute cases |
|                  | up to 90% in perinatally exposed transition to chronic hepatitis|
+------------------+--------------------------------+-------------------------------+
| Vaccine Status   | **Highly effective 3-dose      | **NO VACCINE AVAILABLE** due  |
|                  | vaccine series** available.    | to hypervariable envelope gene|
+------------------+--------------------------------+-------------------------------+
| Definitive Cure  | Functional suppressive control | **>95% CURABLE** with 8-12    |
|                  | (Entecavir, Tenofovir); cure <1%| weeks of oral DAAs (Epclusa) |
+------------------+--------------------------------+-------------------------------+

Hepatitis B Virus (HBV) Serology & Universal Immunization

HBV is 50 to 100 times more infectious than HIV parenterally. It is readily transmitted through minute quantities of blood, saliva, vaginal fluids, and semen. Because of its extreme environmental durability (persisting infectious on dry surfaces for over seven days), sharing toothbrushes, razors, or tattoo needles carries high risk.

• Serologic Interpretation:
  • HBsAg (Hepatitis B Surface Antigen): Marks active infection (acute or chronic). If present >6 months, confirms chronic infection.
  • Anti-HBs (Hepatitis B Surface Antibody): Indicates immunity and clinical protection (resulting either from successful vaccination or resolved natural infection).
  • Anti-HBc (Total Hepatitis B Core Antibody): Appears at the onset of symptoms and persists for life; indicates past or present natural infection (never present after vaccination alone).
  • IgM anti-HBc: Indicates acute or recent infection within the preceding 6 months.
• Universal Vaccine Recommendation: All non-immune clients presenting to addiction treatment facilities must be offered the 3-dose recombinant Hepatitis B vaccine series (at 0, 1, and 6 months) or the 2-dose series (Heplisav-B at 0 and 1 month).

The Direct-Acting Antiviral (DAA) Revolution for Hepatitis C

Historically, HCV was treated with pegylated interferon-alpha and ribavirin—a grueling 48-week regimen associated with intolerable neuropsychiatric toxicity (profound depression, acute psychosis, suicidality) and dismal 40% cure rates. The advent of Direct-Acting Antivirals (DAAs) revolutionized hepatology:

• Mechanisms of Action: DAAs target non-structural proteins vital to HCV viral replication:
  • NS3/4A Protease Inhibitors (suffix "-previr", e.g., glecaprevir)
  • NS5A Replication Complex Inhibitors (suffix "-asvir", e.g., velpatasvir, pibrentasvir)
  • NS5B RNA-Dependent RNA Polymerase Inhibitors (suffix "-buvir", e.g., sofosbuvir)
• Efficacy: All-oral pan-genotypic regimens (such as sofosbuvir/velpatasvir [Epclusa] or glecaprevir/pibrentasvir [Mavyret]) achieve a Sustained Virologic Response at 12 weeks (SVR12)—operationalized as a complete biological cure—in over 95% to 98% of treated individuals across 8 to 12 weeks of once-daily therapy with virtually zero severe side effects.

Dismantling Abstinence Barriers to HCV Treatment

Historically, private insurers, state Medicaid agencies, and medical clinics enforced discriminatory "sobriety restrictions," requiring clients to demonstrate 6 to 12 months of documented negative drug toxicology before approving DAA treatment:

• The AASLD/IDSA Consensus: Clinical guidance from the American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) unequivocally states that active substance use, enrollment in medications for opioid use disorder (MOUD), and positive urine drug screens must NEVER serve as exclusion criteria or prerequisites to deny curative DAA therapy.
• Treatment as Prevention (TasP): Empirical data demonstrate that adherence and cure rates among people who actively inject drugs match those of non-drug-using populations (>95%). Furthermore, curing HCV in active drug users eradicates transmission vectors, producing profound community-wide prevention benefits.

---

Sexually Transmitted Infections (STIs) in Substance Use

Substance intoxication impairs cognitive judgment, blunts risk appraisal, and frequently coincides with transactional sex, leading to dramatic epidemics of bacterial STIs:

The Resurgence of Syphilis (Treponema pallidum)

Syphilis incidence has surged catastrophically across North America, driven largely by co-occurring methamphetamine and crack cocaine use. Syphilis unfolds across distinct clinical stages:

1. Primary Syphilis: Emergence of a solitary, indurated, painless ulcer (chancre) at the site of inoculation (genitals, rectum, mouth). Because it is painless, it often goes unnoticed and heals spontaneously within 3 to 6 weeks, lulling the client into false security.
2. Secondary Syphilis: Manifests 4 to 10 weeks later as a systemic spirochetemia: diffuse, non-pruritic maculopapular rash characteristically appearing on the palms of the hands and soles of the feet; moist, painless, highly infectious wart-like lesions in warm intertriginous folds (condyloma lata); generalized lymphadenopathy; fever; and patchy alopecia.
3. Latent Syphilis: Clinically silent infection detectable solely by serology (RPR/VDRL with confirmatory treponemal tests). Divided into early latent (<1 year duration) and late latent (>1 year).
4. Tertiary & Neurosyphilis: Chronic destructive granulomatous lesions (gummas), cardiovascular aortitis, and central nervous system invasion. Manifestations include meningovascular stroke, general paresis (dementia, personality changes), tabes dorsalis (sensory ataxia), and Argyll Robertson pupils (pupils that accommodate to near objects but fail to react to light).

• Congenital Syphilis Crisis: Pregnant women with active substance use disorders experience high rates of untreated syphilis, causing devastating vertical transmission: spontaneous abortion, stillbirth, non-immune hydrops fetalis, skeletal deformities (saber shins, saddle nose), and infant death. Routine prenatal screening and aggressive treatment with intramuscular benzathine penicillin G are mandatory.

Gonorrhea & Chlamydia

• Neisseria gonorrhoeae & Chlamydia trachomatis: Obligate mucosal pathogens causing purulent urethritis, cervicitis, and proctitis. If untreated, ascending infection produces Pelvic Inflammatory Disease (PID) in women, leading to salpingitis, tubo-ovarian abscesses, ectopic pregnancies, and permanent tubal infertility.
• Treatment Challenges: Widespread emergence of multi-drug-resistant N. gonorrhoeae necessitates high-dose intramuscular ceftriaxone (500 mg IM) monotherapy, while Chlamydia is treated with oral doxycycline (100 mg BID for 7 days).

---

Harm Reduction: Syringe Services Programs (SSPs) & Infection Control

Syringe Services Programs (SSPs)—historically designated needle exchanges—are evidenced-based public health interventions providing comprehensive harm reduction supplies and linkage to clinical care:

Incontrovertible Evidence Base

Rigorous meta-analyses and CDC surveillance confirm that SSPs:

• Reduce HIV and HCV incidence by approximately 50% across communities where they operate.
• Do NOT increase illegal drug consumption, frequency of injection, or neighborhood crime rates.
• Individuals who regularly utilize SSPs are five times more likely to enter substance use disorder treatment and three times more likely to achieve sustained drug cessation than non-participants.

Specialized Harm Reduction Equipment & Safer Injection Guidance

SSPs distribute specialized paraphernalia designed to neutralize specific infection pathways:

• Sterile Water Ampoules: Prevent the use of contaminated tap, toilet, or puddle water, eliminating severe systemic infections caused by Pseudomonas aeruginosa and fungal endophthalmitis.
• Single-Use Sterile Cookers: Reusing shared cookers serves as an efficient transmission vehicle for HCV, even when individuals use fresh needles.
• Micro-Filters (0.22 Micron Wheel Filters): Replace cigarette filters or cotton balls, which trap particulate binders and prevent "Cotton Fever"—a sudden, acute, debilitating febrile reaction caused by endotoxins from the bacterium Pantoea agglomerans that colonizes damp cotton plants.
• Safer Venipuncture Education: Counselors train clients to inject with the needle bevel facing upward, angle needle at 15–45 degrees in the direction of venous blood flow (toward the heart), rotate injection sites systematically, and strictly avoid catastrophic anatomical zones—specifically the femoral vein in the groin (risk of femoral artery puncture, deep vein thrombosis, and gangrene) and the jugular vein in the neck (risk of carotid artery laceration, pneumothorax, and stroke).

---

Airborne Infection Control: Tuberculosis (TB) in Congregate Settings

Mycobacterium tuberculosis is an acid-fast bacillus transmitted via aerosolized droplet nuclei produced when an individual with active pulmonary disease coughs, sneezes, or speaks. In congregate residential addiction treatment centers, halfway houses, and medical detox units, TB represents an acute public health hazard.

+-----------------------------------------------------------------------------------+
|              LATENT TB INFECTION (LTBI) VS. ACTIVE CONTAGIOUS TB DISEASE          |
+-----------------------------------------------------------------------------------+
| Clinical Parameter        | Latent TB Infection (LTBI)     | Active Pulmonary TB Disease  |
+---------------------------+--------------------------------+------------------------------+
| Bacterial Multiplication  | Dormant within granulomas      | Actively multiplying         |
| Contagiousness / Spread   | **Cannot spread to others**    | **Highly contagious/airborne**|
| Clinical Symptoms         | Completely asymptomatic        | Cough >3 weeks, hemoptysis,  |
|                           |                                | night sweats, fever, weight loss
| Chest Radiography         | Completely normal              | Abnormal: cavitary lesions,  |
|                           |                                | apical infiltrates           |
| Sputum Smear / Culture    | Negative acid-fast bacilli     | Positive acid-fast bacilli   |
| PPD / IGRA Blood Test     | **Positive**                   | **Positive**                 |
| Clinical Action           | Preventive pharmacotherapy     | Immediate airborne isolation |
|                           | (e.g., Rifampin or Isoniazid)  | in AIIR + 4-drug RIPE therapy|
+-----------------------------------------------------------------------------------+

Mantoux Tuberculin Skin Test (TST / PPD) Interpretation

The Mantoux test involves intradermal injection of 5 tuberculin units (0.1 mL) of purified protein derivative (PPD) into the volar forearm. The reaction must be read by a trained healthcare professional 48 to 72 hours post-injection:

[!NOTE] The Cardinal Rule of TST Reading: The reader must measure the transverse diameter of palpable induration (hard, elevated tissue) in millimeters across the forearm, completely ignoring erythema (skin redness). Redness without induration is clinically meaningless.

• Cutoff Criteria:
  • >= 5 mm Induration: Positive in HIV-positive individuals, recent contacts of active TB cases, or immunosuppressed clients.
  • >= 10 mm Induration: Positive in people who inject drugs, residents and staff of high-risk congregate living settings (substance use treatment facilities, homeless shelters, correctional institutions), and medically underserved populations.
  • >= 15 mm Induration: Positive in persons with no known risk factors for tuberculosis.
• Interferon-Gamma Release Assays (IGRAs): Blood tests (QuantiFERON-TB Gold Plus, T-SPOT) that measure T-cell release of interferon-gamma in response to specific M. tuberculosis antigens. IGRAs require only one clinical visit and are not confounded by prior Bacillus Calmette-Guérin (BCG) vaccination, which causes false-positive PPD skin tests.

---

Infectious Disease Summary Matrix